Phase II study of combination therapy of cisplatin suspension in lipiodol and 5-fluorouracil hepatic arterial infusion for advanced HCC
|Complete: follow-up complete
|Health condition(s) or Problem(s) studied
|Date of first enrollment
|Target sample size
|Countries of recruitment
|hospitalization therapy administration via the implanted port of Cisplatin/lipiodol suspension(50mg/body,ia,day1,8) and 5-FU(1250mg/body/day, cia day1-5,8-12) into the hepatic artery every two weeks. outpatient therapy : The case that chemotherapy by the hospitalization finished,leaves the hospital if possible. Administration via the implanted port of Cisplatin/lipiodol suspension(10~50mg/body,ia,day1)and 5-FU(500~1250mg/body/day,cia,day1-5)into the hepatic artery every two weeks.Repeat 10 courses.
|Progrssion free survival
|Overall survival response evaluation complicasion
Key inclusion & exclusion criteria
|Male and Female
|1.previous chemotherapy or TAE 2.Previous operation or RFA or PEIT within one year 3.Extrahepatic metastasis or nodes metastasis 4.Concurrent infections(without hepatitis virus) 5.Active double cancers 6.Medical history of severe hypersensitivity. 7.Pregnant,lacting women or women with suspected pregnancy. 8.Inappropriate patients for this study judged by physicians.
|Division of Gastroenterology,Kurume University School of Medicine
|Source(s) of Monetary Support
|Yame General Hospital Department of Gastroenterology and Hepatology
|Kurume University School of Medicine Division of Gastroenterology